# EPCORE DLBCL-2: HCP commentary report

> 187 verified statements (70 from clinicians verified by NPI or staff page) from 55 commentary sources · 12 findings · updated Oct 31, 2026

## Report

- Trial: A Phase 3, Randomized, Open-Label Study to Evaluate Safety and Efficacy of Epcoritamab in Combination With R-CHOP Compared to R-CHOP in Subjects With Newly Diagnosed Diffuse Large B-Cell Lymphoma (DLBCL)
- NCT ID: NCT05578976
- Registry: https://clinicaltrials.gov/study/NCT05578976
- Sponsor: Genmab
- Phase: Phase 3
- Status: Active, not recruiting
- Drugs tested: epcoritamab
- Indication: newly diagnosed diffuse large B-cell lymphoma
- Version: v1.0.0, edition 1
- Accepted: 2026-10-31
- Last checked: 2026-10-31
- Release hash: 319cb6fe50ae8c9b8fef961112c6e66b51750a2743546e3d549e472a52287feb

## Counts

- HCP commentary sources screened: 83
- Sources cited by verified statements: 55
- Verified statements: 187
- From speakers with a confirmed clinical role (verified by the NPI registry or their own institution's staff page): 70
- Findings: 12
- Named people in screened sources (unnamed speakers and accounts not counted): 39
- Voices cited: 39
- Cited voices identity-verified: 29
- Organisational or shared accounts (not counted as people): 8

Counts describe the retained sources. They do not estimate how many HCPs hold a view.

## Abstract

Clinician commentary on EPCORE DLBCL-2 in the sources reviewed for this edition leads to one open question: What absolute benefit, survival, safety, subgroup and delivery evidence would justify adding treatment rather than continuing an established frontline option? Its leading findings: (1) the central disagreement is what PFS improvement must prove before practice changes. (2) numerical safety and deaths—not qualitative reassurance—are pivotal to interpretation. (3) the actual treatment choice remains unresolved: R-CHOP, Pola-R-CHP or epcoritamab plus R-CHOP. 9 more findings follow. 83 sources screened, 55 cited; not all HCPs or all public discussion.

## Open Medical Affairs question

What absolute benefit, survival, safety, subgroup and delivery evidence would justify adding treatment rather than continuing an established frontline option?

Raised by the leading finding. The report shows what clinicians said and the sources behind it; it does not settle the question.

## Findings (titles)

- F1. The central disagreement is what PFS improvement must prove before practice changes
- F2. Numerical safety and deaths—not qualitative reassurance—are pivotal to interpretation
- F3. The actual treatment choice remains unresolved: R-CHOP, Pola-R-CHP or epcoritamab plus R-CHOP
- F4. Some reactions are emphatic, but most practice-change language remains prospective
- F5. Risk selection is central; benefit should not be assumed uniform across eligible patients
- F6. EPCORE NHL-2 supplied the rationale, not a randomized estimate of frontline benefit
- F7. Interim timing, independent review and unequal randomization shape confidence in the signal
- F8. Duration and scheduling raise questions about additional treatment burden and trial design
- F9. Access, capacity and cost could determine whether a promising regimen is deliverable
- F10. Molecular response is proposed as a route to selective escalation—and eventually less treatment
- F11. Open sequencing questions coexist with predictions of a sharp decline in cellular therapy
- F12. Regulatory fit and the competing evidence base remain conditional

## What sits behind each finding

Counts describe what the report retained, not how many clinicians hold a view. A statement can support more than one finding.

| Finding | Statements | Passages | Sources | Named voices | Counterview | Limitations |
| --- | ---: | ---: | ---: | ---: | --- | ---: |
| F1 | 5 | 5 | 4 | 4 | recorded | 2 |
| F2 | 14 | 6 | 6 | 4 | recorded | 3 |
| F3 | 17 | 11 | 8 | 8 | recorded | 3 |
| F4 | 21 | 19 | 19 | 18 | recorded | 3 |
| F5 | 20 | 13 | 11 | 9 | recorded | 4 |
| F6 | 24 | 11 | 9 | 6 | recorded | 3 |
| F7 | 15 | 6 | 6 | 5 | recorded | 3 |
| F8 | 11 | 9 | 5 | 8 | recorded | 3 |
| F9 | 15 | 16 | 14 | 13 | recorded | 3 |
| F10 | 8 | 6 | 5 | 5 | none recorded | 3 |
| F11 | 9 | 8 | 8 | 6 | recorded | 5 |
| F12 | 24 | 13 | 12 | 10 | recorded | 4 |

### What the statements are

| Finding | Views | Questions and uncertainty | Clinical experience | Comparisons | Restated results and context | Passages supporting | Passages giving context | Sources by kind | Feeds the Medical Affairs question |
| --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | --- | --- |
| F1 | 4 | 0 | 0 | 1 | 0 | 5 | 0 | 4 posts and articles | yes |
| F2 | 6 | 6 | 0 | 0 | 2 | 15 | 0 | 6 posts and articles | yes |
| F3 | 5 | 1 | 1 | 10 | 0 | 18 | 2 | 8 posts and articles | yes |
| F4 | 18 | 1 | 1 | 1 | 0 | 24 | 1 | 19 posts and articles | no |
| F5 | 14 | 4 | 1 | 0 | 1 | 22 | 1 | 9 posts and articles, 2 podcasts and video | yes |
| F6 | 11 | 0 | 2 | 3 | 8 | 30 | 1 | 7 posts and articles, 2 podcasts and video | no |
| F7 | 2 | 4 | 0 | 1 | 8 | 17 | 1 | 6 posts and articles | yes |
| F8 | 5 | 2 | 0 | 1 | 3 | 11 | 1 | 4 posts and articles, 1 podcast or video | yes |
| F9 | 9 | 3 | 2 | 0 | 1 | 15 | 2 | 12 posts and articles, 2 podcasts and video | yes |
| F10 | 5 | 3 | 0 | 0 | 0 | 8 | 0 | 4 posts and articles, 1 podcast or video | yes |
| F11 | 7 | 1 | 0 | 0 | 1 | 9 | 2 | 8 posts and articles | yes |
| F12 | 10 | 2 | 0 | 4 | 8 | 28 | 2 | 12 posts and articles | yes |

### Trial dimensions

- Primary endpoint: Number of Participants with Progression-Free Survival (PFS) with an International Prognostic Index (IPI) of 3-5: F1 (4 shared claims), F2 (2 shared claims), F3 (1 shared claims), F4 (9 shared claims), F5 (2 shared claims), F7 (11 shared claims), F12 (4 shared claims)
- Secondary endpoints: F1 (5 shared claims), F2 (10 shared claims), F3 (1 shared claims), F4 (4 shared claims), F5 (6 shared claims), F6 (6 shared claims), F7 (3 shared claims), F8 (1 shared claims), F9 (5 shared claims), F10 (7 shared claims), F11 (2 shared claims), F12 (5 shared claims)
- Population and setting: F2 (3 shared claims), F3 (3 shared claims), F4 (1 shared claims), F5 (19 shared claims), F6 (2 shared claims), F7 (2 shared claims), F9 (3 shared claims), F10 (1 shared claims), F11 (2 shared claims), F12 (2 shared claims)
- The comparison: F3 (1 shared claims), F5 (1 shared claims), F6 (1 shared claims), F7 (3 shared claims), F8 (4 shared claims), F9 (1 shared claims), F10 (1 shared claims)
- Safety and tolerability: F1 (2 shared claims), F2 (14 shared claims), F3 (1 shared claims), F4 (4 shared claims), F5 (5 shared claims), F6 (7 shared claims), F7 (4 shared claims), F8 (1 shared claims), F9 (8 shared claims), F10 (3 shared claims), F11 (1 shared claims), F12 (6 shared claims)
- Design and conduct: F2 (2 shared claims), F3 (3 shared claims), F5 (3 shared claims), F6 (8 shared claims), F7 (14 shared claims), F8 (8 shared claims), F9 (1 shared claims), F10 (1 shared claims)

## Sample findings

Paraphrased; the full report links each statement to its source.

## What's inside

| Section | Items | Access |
| --- | ---: | --- |
| Findings with interpretation, counterviews and limits | 12 | Titles free |
| Detailed analysis | 13 sections | Paid |
| Verified statements with short source quotes and links | 187 | Paid |
| Trial aspects mapped | 12 | Free |
| Sources with links | 55 | Counts free |
| Speaker attribution for cited voices | 39 | Paid |

## Trial aspects

12 discussed · 0 no commentary found · 0 assessment incomplete.

| Aspect | Coverage | Statements | Sources |
| --- | --- | ---: | ---: |
| Primary endpoint: Number of Participants with Progression-Free Survival (PFS) with an International Prognostic Index (IPI) of 3-5 | discussed | 46 | 28 |
| Secondary endpoints | discussed | 36 | 22 |
| Population and setting | discussed | 25 | 14 |
| The comparison | discussed | 12 | 9 |
| Safety and tolerability | discussed | 37 | 25 |
| Design and conduct | discussed | 36 | 16 |
| Current treatment choices and comparative positioning | discussed | 53 | 19 |
| Earlier-line rationale and the EPCORE NHL-2 evidence bridge | discussed | 36 | 14 |
| Treatment duration, scheduling and response-guided evidence generation | discussed | 15 | 6 |
| Delivery capacity, affordability, patient support and referral | discussed | 15 | 14 |
| Downstream cellular therapy, prior-target exposure and later-line research | discussed | 9 | 8 |
| Regulatory interpretation and geographic applicability | discussed | 21 | 12 |

An aspect marked incomplete is a question the public commentary did not let us answer. We show it rather than hide it.

## Sources

| Channel | Screened | Cited |
| --- | ---: | ---: |
| X threads | 67 | 43 |
| LinkedIn posts | 6 | 6 |
| Bluesky threads | 6 | 2 |
| Podcasts | 2 | 2 |
| YouTube | 2 | 2 |

- Screened window: 2023-06-15 to 2026-10-29
- Cited window: 2023-06-15 to 2026-10-29
- Retrieved: 2026-10-31

Screened sources were retrieved for this trial. Cited sources back at least one verified statement and include primary sources used for context.

## The trial

From ClinicalTrials.gov.

- Title: A Phase 3, Randomized, Open-Label Study to Evaluate Safety and Efficacy of Epcoritamab in Combination With R-CHOP Compared to R-CHOP in Subjects With Newly Diagnosed Diffuse Large B-Cell Lymphoma (DLBCL)
- Registry: NCT05578976 (https://clinicaltrials.gov/study/NCT05578976)
- Study IDs: M20-621 · 2023-505277-32 (EU CT)
- Sponsor: Genmab
- Design: Phase 3 · interventional, randomized, parallel, phase3
- Status: Active, not recruiting
- Enrollment: 900 (estimated)
- Start: 2023-02-08 (actual)
- Primary completion: 2027-06 (estimated)
- Primary endpoint: Number of Participants with Progression-Free Survival (PFS) with an International Prognostic Index (IPI) of 3-5 (Up to Approximately 46 Months)
- Intervention: Epcoritamab (drug)
- Intervention: Cyclophosphamide (drug)
- Intervention: Rituximab (drug)
- Intervention: Vincristine (drug)
- Intervention: Doxorubicin (drug)
- Intervention: Prednisone (drug)

## Scope and limits

This report does not judge efficacy, estimate HCP prevalence or consensus or give treatment advice.

- Discussion that does not name the trial may be missing from this edition.
- Not yet captured in this edition: a view on alternative bispecific-antibody chemotherapy strategies for previously untreated intermediate- or high-risk diffuse large B-cell lymphoma.
- Not yet captured in this edition: a view on biology-guided selection of targeted additions to frontline treatment in newly diagnosed diffuse large B-cell lymphoma.
- Not yet captured in this edition: a view on frontline CAR-T as an alternative to chemoimmunotherapy escalation in very-high-risk newly diagnosed lymphoma.
- Not yet captured in this edition: a view on targeted additions to frontline chemotherapy for high-risk newly diagnosed diffuse large B-cell lymphoma.
- Not yet captured in this edition: a view on frontline epcoritamab plus R-CHOP efficacy, safety and the need for randomized evidence.
- Not yet captured in this edition: a view on frontline bispecific escalation using an alternative chemoimmunotherapy backbone in newly diagnosed diffuse large B-cell lymphoma.
- Some passages in the sources used in this report were not fully assessed for clinician views, so a view there may be missing from this edition.
- 75 statements in the sources reviewed for this edition are about other patients or topics, or only mention the trial, and are not counted.
- Further source limits: discussion that describes the trial without naming it may be incomplete; some discussion that describes the trial without naming it may be missing; sources about other trials are not included.
- The sources reviewed for this edition do not represent all HCPs or all public discussion. Some relevant passages were not fully assessed, and unnamed or differently worded references may be missing.
- Source totals do not measure independent HCP support: the material includes repeated posts, quoted announcements, organizational accounts and reactions to the same information.
- No original results publication or full protocol for EPCORE DLBCL-2 was available. Phase III result descriptions are largely sponsor topline information relayed through commentary, and some methods are secondary descriptions.
- At the time of the cited topline discussions, absolute PFS by arm, OS, detailed response and safety outcomes, follow-up, event counts and geographic enrollment were not fully reported. Their absence cannot establish no benefit, no harm or lack of applicability.
- Earlier EPCORE NHL-2 findings concern a small high-risk cohort, different treatment exposure and different reporting time points. They cannot be pooled with, or substituted for, randomized EPCORE DLBCL-2 outcomes.
- Some speakers' identities or clinical roles are not established in the sources used in this report; each statement is attributed only as far as its source shows.
- This edition does not fully capture the February 2026 reasons for selecting or withholding alternative frontline regimens, or every conditional question about subsequent cellular therapy. It should not be used as a complete account of those exchanges.
- Predictions about standard of care, cure, CAR-T displacement, later-line research funding, regulatory pathways and timing remain predictions. References to other settings are used only where the speaker explicitly applies them to interpreting this frontline decision.
- Post and publication dates are not necessarily session dates. Pre-result expectations, earlier-study interviews and topline reactions do not establish changes of mind. Speculation about ASH does not confirm a scheduled full-data presentation.

How reports are built and checked: https://www.erudio.com/methods

## Editions and corrections

- v1.0.0, accepted 2026-10-31: current edition

Last checked for new commentary 2026-10-31. No corrections. Versions follow semver: a new or changed finding is a minor version, more evidence without a material change is a patch.

## Offer

- Size: Standard (187 verified statements)
- Current edition: $1,250. A purchase starts a check for new commentary and any newer edition follows at no charge
- 3 months of weekly updates: $2,200
- 6 months of weekly updates: $3,100
- 12 months of weekly updates: $4,400
- Optional identity linkages (12-month updates only, product updates-12-identities; speakers are named and described in every report): NPI and other verified IDs at $15 per identity-verified person in the edition at purchase (29 now), at most $1,250; people verified later in the term at no charge
- Pricing: https://www.erudio.com/pricing
- Buy now (card, through Stripe): https://www.erudio.com/reports/epcore-dlbcl-2-nct05578976
- Agents: POST https://www.erudio.com/api/orders with {"report": "epcore-dlbcl-2-nct05578976", "product": "edition" | "updates-3" | "updates-6" | "updates-12" | "updates-12-identities", "buyer_email": "...", "licence_key": "<your key, if you hold one>"}; it returns a payment link for your user (and a pay_url your own MPP or x402 payment client can pay over HTTP 402, when offered), and once paid the status_url returns your license key. Send the same key with every later order so all reports sit on one key. The buyer gets their account key by email, which reads every report bought with their address; recover_key (POST https://www.erudio.com/api/keys/recover) sends it again
- Talk to Audun Utengen and Tom Lee (invoice, PO, questions): https://www.erudio.com/contact?report=epcore-dlbcl-2-05578976

## Cite

Erudio Health. EPCORE DLBCL-2 (NCT05578976): HCP commentary report. Edition 1, v1.0.0. Accepted Oct 31, 2026. https://www.erudio.com/reports/epcore-dlbcl-2-nct05578976

## Machine access

- JSON: https://www.erudio.com/reports/epcore-dlbcl-2-nct05578976.json
- Markdown: https://www.erudio.com/reports/epcore-dlbcl-2-nct05578976.md
- MCP, no sign-in: https://mcp.erudio.com/free, tool `get_report_card` with `{"slug": "epcore-dlbcl-2-05578976"}`